Insight Molecular Diagnostics Inc. (IMDX) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $135.62M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Joshua Riggs |
| IPO Date | 2015-12-30 | CAGR | — |
| Employees | 57 | Website | imdxinc.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $193.78M | P/E | -2.82 | Forward P/E | -5.25 | PEG | — |
| P/S | 23.49 | P/B | -2.09 | P/CF | -1.65 | P/FCF | -1.33 |
| Sales | $1.67M | Sales 1Y | -60.77% | Sales 3Y | 51.68% | Sales 5Y | -60.35% |
| EPS | $-1.49 | EPS 1Y | -56.27% | EPS 3Y | -84.65% | EPS 5Y | -79.15% |
| Sales QoQ | 646.88% | EPS QoQ | 158.33% | Sales QoQ Avg | 209.49% | EPS QoQ Avg | 51.67% |
| Gross Margin | 11.17% | Operating Margin | -2558.74% | Profit Margin | -2955.63% | ROCE | -223.06% |
| ROA | -168% | ROE | 272% | Altman Z Score | -23.11 | Piotroski Score | 1 |
| Current Ratio | 2 | Quick Ratio | 1.98 | Cash Ratio | 1.73 | Op. CF Ratio | -0.9 |
| Debt/Equity | -0.12 | Debt/Assets | 0.09 | Lt Debt/Equity | -0.04 | Lt Debt/Cap. | -0.04 |
| Intrst Cov. | -436.03 | Inventory Turnover | 7.17 | Asset Turnover | 0.06 | Receivables Turnover | 8.7 |
| Enterprise Value | $193.78M | P/E Ratio | -2.82 |
| Forward P/E | -5.25 | PEG Ratio | — |
| P/S Ratio | 23.49 | P/B Ratio | -2.09 |
| P/CF Ratio | -1.65 | P/FCF Ratio | -1.33 |
| EPS | $-1.49 | EPS Growth 1Y | -56.27% |
| EPS Growth 3Y | -84.65% | EPS Growth 5Y | -79.15% |
| Revenue Growth 1Y | -60.77% | Gross Margin | 0.11% |
| Operating Margin | -25.59% | Profit Margin | -29.56% |
| ROE | 2.72% | ROA | -1.68% |
| ROCE | -2.23% | Current Ratio | 2 |
| Quick Ratio | 1.98 | Cash Ratio | 1.73 |
| Debt/Equity | -0.12 | Interest Coverage | -436.03 |
| Altman Z Score | -23.11 | Piotroski Score | 1 |
Insight Molecular Diagnostics Inc. (IMDX) valuation & financials
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $135.62M and trades at a price-to-earnings ratio of -2.8. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Insight Molecular Diagnostics Inc.'s revenue grew -60.8% over the last year.
Insight Molecular Diagnostics Inc.'s next earnings report is scheduled for November 9, 2026 after market close; analysts estimate EPS of $-0.23. Check the earnings calendar to see all companies reporting this week.
Insight Molecular Diagnostics Inc. (IMDX) — frequently asked questions
When does Insight Molecular Diagnostics Inc. (IMDX) report earnings next?
Insight Molecular Diagnostics Inc. is expected to report earnings on November 9, 2026 after market close. Analysts estimate EPS of $-0.23.
What is Insight Molecular Diagnostics Inc.'s market cap?
Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $135.62M.
What is IMDX's P/E ratio?
Insight Molecular Diagnostics Inc. trades at a price-to-earnings ratio of -2.8, with trailing twelve-month EPS of $-1.49.
How fast is Insight Molecular Diagnostics Inc. growing?
Insight Molecular Diagnostics Inc.'s revenue grew -60.8% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)
Insight Molecular Diagnostics Inc. revenue & earnings charts →